'Skinny' generic Vascepa label case reaches US Supreme Court

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

Generic drugmaker Hikma pledges $1bn in US investment

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

Jazz pays $145m to resolve Xyrem antitrust disputes

Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

Hikma will pay $150m in US opioid settlement

Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al

Amarin hit hard as generics loom for fish oil drug Vascepa